Addressing the Risks of Chemo-Induced Myelosuppression in SCLC


ASCO® 2023 Insights: "Final Survival Data From a Randomized Phase 2 Trial Comparing High-Dose With Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited Stage SCLC"

83 views
June 9, 2023
Comments 0
Login to view comments. Click here to Login